Usted buscó: recombinant (Sueco - Finés)

recombinant human acid sphingomyelinase
recombinant human acid sphingomyelinase

recombinant human c1 - inhibitor
recombinant human c1 - inhibitor

recombinant human porphobilinogen deaminase
recombinant human porphobilinogen deaminase

recombinant human acid α- glucosidase
recombinant human acid α- glucosidase

recombinant human alpha- 1 antitrypsin
recombinant human alpha- 1 antitrypsin

myristolated- peptidyl - recombinant human cd59
myristolated- peptidyl - recombinant human cd59

recombinant human monoclonal antibody to hsp90
recombinant human monoclonal antibody to hsp90

gly2- recombinant human glucagon- like peptide
gly2- recombinant human glucagon- like peptide

clinical investigation of recombinant factor viii and ix products
clinical investigation of recombinant factor viii and ix products

recombinant coagulation factor ix products note for guidance on the clinical
recombinant coagulation factor ix products note for guidance on the clinical

core spc for human plasma derived and recombinant coagulation factor ix products
core spc for human plasma derived and recombinant coagulation factor ix products

recombinant glycoprotein gp350 of epstein- barr virus (henogen 350)
recombinant glycoprotein gp350 of epstein- barr virus (henogen 350)

recombinant hepatitis b virus small surface antigen (hbsag) part a
recombinant hepatitis b virus small surface antigen (hbsag) part a

myristolated- peptidyl - recombinant scr1- 3 of human complement receptor type i
myristolated- peptidyl - recombinant scr1- 3 of human complement receptor type i

0, 40 milligram al3+ adsorberad till aluminiumfosfat 3 producerat i saccharomyces cerevisae- celler med recombinant dna- teknik
0, 40 milligrammaa al3+ imeytetty alumiinifosfaattiin 3 tuotettu dna geenitekniikalla muunnelluissa saccharomyces cerevisiae soluissa. am

dokumenttitel requirements and controls applied to bovine serum used in the production of immunological veterinary medicinal products eu requirements for batches with maximum and minimum titre or batch potency for developmental safety and efficacy studies requirements for live recombinant vectored vaccines requirements for compatibility statements for veterinary vaccines harmonisation of requirements for potency and batch consistency of vaccines vich:
asiakirjan nimi requirements and controls applied to bovine serum used in the production of immunological veterinary medicinal products eu requirements for batches with maximum and minimum titre or batch potency for developmental safety and efficacy studies requirements for live recombinant vectored vaccines requirements for compatibility statements for veterinary vaccines harmonisation of requirements for potency and batch consistency of vaccines vich:

pertussis toxoid, adsorbed 25 µg filamentous haemagglutinin, adsorbed 25 µg pertactin, adsorbed 8 µ g recombinant hepatitis b surface antigen (s protein), adsorbed 10 µg inactivated type 1 poliovirus 40 du inactivated type 2 poliovirus 8 du inactivated type 3 poliovirus 32 du conjugate of haemophilus influenzae type b capsular polysaccharide (prp) 10 µg and tetanus toxoid (t), adsorbed (prp- t) 20- 40 µg
pertussis toxoid, adsorbed 25 µg filamentous haemagglutinin, adsorbed 25 µg pertactin, adsorbed 8 µ g recombinant hepatitis b surface antigen (s protein), adsorbed 10 µg inactivated type 1 poliovirus 40 du inactivated type 2 poliovirus 8 du inactivated type 3 poliovirus 32 du conjugate of haemophilus influenzae type b capsular polysaccharide (prp) 10 µg and tetanus toxoid (t), adsorbed (prp- t) 20- 40 µg